Organic Active Ingredients TRIZ Cases

Flexible adhesive patch reduces systemic toxicity by delivering controlled lidocaine doses to pain sites.

Non-lamellar SNALP formulations resolve rapid clearance and toxicity issues in systemic gene delivery.

PPAR agonist compounds induce osteoblast and chondroblast differentiation in mammalian stem cells to treat osteoporosis and osteoarthritis.

Chroman 1 and Emricasan compositions prevent apoptosis during enzymatic dissociation, enabling high single-cell survival rates.

Covalently linked PAMAM dendrimers penetrate the blood-brain barrier to deliver chemotherapeutic agents, resolving low tumor uptake and off-target toxicity.

IgE antibodies target tumor stroma antigens to trigger mast cell activation and increase local permeability.

Engineered flavin-dependent halogenase variants catalyze specific halogenation of complex organic compounds.

Large lipid globules coated with phospholipids replicate breast milk structure to reduce infant fat mass and obesity risk.

Minitablets with pH-independent film coating mask bitter entrectinib taste, improving pediatric swallowability without compromising bioavailability consistency.

Silyl ether protection enables selective rapamycin alkylation, reducing by-product formation and improving everolimus yield.

Larger eszopiclone particles reduce surface area exposure, preventing hydrolysis and impurity formation during tablet storage.

Genotyping methods identify ADCY9 polymorphisms to predict patient response to CETP inhibitor therapy.

Phenylpropionic acids induce pili formation in Bifidobacterium, resolving the bottleneck of poor intestinal colonization under general culture conditions.

Pyrazolo[1,5-a]pyrimidine compounds inhibit adaptor associated kinase 1 activity to address unmet needs in treating schizophrenia and Alzheimer's disease.

Combining magnolia bark extract with L-arginine N-alpha-lauroyl ethyl ester inhibits plaque biofilm formation through synergistic action.

Modular pyrazole compounds block NF-kB-inducing kinase to reduce tumor growth and treat inflammatory disorders.

Morus alba L. extract addresses inadequate single-target NAFLD treatments by regulating fatty acid synthesis and oxidation to reduce liver lipid content.

4-Azaindole compounds modulate cytokine production by inhibiting TLR7, 8, and 9 signaling to address inadequate specificity in autoimmune treatments.

Segmenting BACE-1 and BACE-2 targets via specific oxazine structures overcomes limited inhibitor availability for Alzheimer's and diabetes.

Single-stranded artificial mimic miRNA inhibits target gene expression while avoiding immune sensor recognition and reducing synthesis costs.

Phosphate buffer maintains 0.6% olopatadine solubility and stability in aqueous nasal spray, eliminating polymeric stabilizers that cause mucosal irritation.

Irdabisant increases dopamine release in the nucleus accumbens, addressing ineffective trial-and-error medication selection for anhedonia.

CCK2 receptor antagonists treat depression and nerve injury pain by blocking specific receptors, avoiding SSRI side effects.

Selective 5-HT4 agonism improves gastric emptying while avoiding adverse cardiac events linked to non-selective treatments.

Strong anion exchange chromatography resolves over-sulfated chondroitin sulfate below 0.05% w/w to ensure pharmaceutical safety.

Repurposed dantrolene decreases viral replication and release to improve clinical outcomes in infected subjects.

Small molecule inhibitors modulate HDR and NHEJ pathways to increase precise genome editing frequency while minimizing off-target effects in stem cells.

Non-coding DNA sequences with N1N2CGN3N4 motifs activate latent HIV reservoirs via innate immune stimulation without triggering harmful adaptive responses.

Novel phenylsulfonamido-benzofuran compounds mimic NOXA to inhibit MCL-1, overcoming treatment resistance in proliferative diseases.

Milling creatine with citric acid creates a co-crystal formulation that boosts aqueous solubility while buffering acidity to protect dental health.

N-methyl tetrahydroquinoline compounds act as positive allosteric modulators on the muscarinic M1 receptor.

Glucuronide prodrugs release tofacitinib via beta-glucuronidase cleavage, achieving high local exposure while minimizing systemic immunosuppression.

Detecting single nucleotide polymorphisms in the SMYD3 gene identifies genetically defined subpopulations for targeted therapeutic intervention.

Combination therapy using mutated SIRPαD1-Fc and azacitidine improves response rates while minimizing hemolytic anemia.

Consensus spike antigen sequences elicit robust humoral and cellular immune responses against diverse SARS-CoV-2 variants.

Bicyclic core compounds inhibit STING activity through direct protein binding, resolving excessive signaling in autoimmune diseases.

Fluorine-substituted cordycepin phosphoramidates bypass adenosine deaminase degradation, eliminating toxic inhibitor requirements.

Controlled crystallization transforms unstable amorphous material into defined alpha and beta forms with improved stability and handling.

Replacing racemic resolution with imine reductase catalysis achieves high enantiomeric excess and chemical purity in (S)-nicotine synthesis.

Oxadiazole compounds inhibit 5-lipoxygenase activating protein to block leukotriene synthesis.

Modified benzimidazolium structures reduce permeability to improve topical efficacy for chronic lung diseases.

Modified nucleoside structures overcome limited treatment options by effectively inhibiting HCV replication in cell-based assays.

Polyphosphoester polymers enhance endosomal release and biodegradability to resolve delivery potency versus patient tolerability trade-offs.

HOG pathway gene inhibitors increase ergosterol biosynthesis, sensitizing fungi to azole drugs and reducing required antifungal dosages.

Sublingual dexmedetomidine spray delivers potent analgesia via transmucosal absorption, resolving the trade-off between pain relief and sedation.

Antisense oligonucleotides reduce TMEM106B protein concentrations to mitigate neurodegenerative disease risks while preserving lysosomal function.

Formula I derivatives enhance brain tissue penetration and anti-tumor efficacy against lung cancer metastasis while maintaining kinase inhibition activity.